# SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer

> **NCT06402435** · PHASE2 · RECRUITING · sponsor: **Hubei Cancer Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Lvonescimab (AK112)

## Key facts

- **NCT ID:** NCT06402435
- **Lead sponsor:** Hubei Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-28
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-09-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06402435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06402435, "SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06402435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*